Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer|April 25, 2003
Hypersensitivity and idiosyncratic reactions to oxaliplatinRebecca R Thomas, Mary G Quinn, Barbara Schuler, et al.
Anti-Cancer Drugs|July 23, 2004
Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapyGregory D Leonard, Michael R Wagner, Mary G Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Acute oxaliplatin-induced peripheral nerve hyperexcitabilityRichard H Wilson, Tanya Lehky, Rebecca R Thomas, et al.
BMC Cancer|September 20, 2005
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerGregory D Leonard, Maurice A Wright, Mary G Quinn, et al.
Oncology Reports|May 5, 2005
A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowelAbdel Salam Attia Ismail, Mary G Quinn, Maurice A Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patientsJean L Grem, Nancy Harold, Bruce Keith, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2003
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorinJean L Grem, Mary G Quinn, Bruce Keith, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumorsMaurice A Wright, Geraldine Morrison, Pengxin Lin, et al.
Pageof 1